Granted Patent
B2
US 12,414,916 · App. 18/192,404 · Granted Sep 16, 2025
Dry powder formulations of epinephrine and associated methods
Inventors:
Scott Lyman (Raleigh, NC); Barry Bleske (Albuquerque, NM); Ted William Lanpher (Half Moon Bay, CA)
Assignee:
Belhaven BioPharma Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.
Claims (22)
1. An intranasal device for administration of a pharmaceutical composition comprising:
a reservoir and a means for discharging one or more doses of the pharmaceutical composition, wherein the reservoir contains a quantity of the pharmaceutical composition;
wherein the pharmaceutical composition is a dry powder comprising:
epinephrine or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition provides a dose of about 0.01 mg to about 10 mg of the epinephrine or the pharmaceutically acceptable salt thereof;
a carrier; and
a citrate;
wherein the pharmaceutical composition does not include an additional vasodilator; and
wherein the intranasal device further includes a nasal probe and an actuator.
2. The intranasal device of claim 1 , wherein a median particle diameter of the epinephrine or the pharmaceutically acceptable salt thereof is about 20 μm to about 75 μm.
3. The intranasal device of claim 1 , wherein the pharmaceutical composition further comprises an anticaking agent.
4. The intranasal device of claim 1 , wherein the pharmaceutical composition further comprises at least one antihistamine.
5. The intranasal device of claim 1 , wherein the pharmaceutical composition further comprises at least one steroid.
6. The intranasal device of claim 1 , wherein the pharmaceutical composition further comprises a catechol-o-methyl transferase (COMT) inhibitor.
7. The intranasal device of claim 1 , wherein the pharmaceutical composition further comprises one or more agents selected from a group consisting of a mucosal permeation or penetration enhancer, a mucoadhesive, a mucosal transit slowing agent, a mucosal transport enhancer, or any combination thereof.
8. The intranasal device of claim 1 , wherein the intranasal device has 360° functionality and is constructed and configured to dispense a dose from any position.
9. The intranasal device of claim 1 , wherein the intranasal device further includes an intranasal device global positioning system (GPS) device or is coupled to a GPS device, wherein the intranasal device GPS or the GPS device is constructed and configured to provide location data.
10. The intranasal device of claim 1 , wherein the intranasal device further includes a communications interface, wherein the communications interface is constructed and configured to transmit data wirelessly to at least one remote device.
11. The intranasal device of claim 1 , wherein the carrier includes mannitol, a cyclodextrin, citric acid, lactose, and/or sodium carboxymethylcellulose.
12. The intranasal device of claim 1 , wherein the pharmaceutical composition does not include a preservative.
13. The intranasal device of claim 1 , wherein the quantity of the pharmaceutical composition is between about 5 mg and about 75 mg.
14. The intranasal device of claim 1 , wherein the intranasal device further includes a sensor that is adapted to detect a displacement or a deformation of a portion of the intranasal device when the dry powder is dispensed from the reservoir.
15. The intranasal device of claim 14 , wherein the intranasal device further includes a display and a power supply, a timer, a clock, and/or a printed circuit board, wherein the display is constructed and configured to display a time of dose dispensation.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 10, 2023
From: LYMAN, SCOTT; BLESKE, BARRY EUGENE; LANPHER, TED WILLIAM
To: BELHAVEN BIOPHARMA INC.
Reel/Frame 063273/0231 →
Continuity (3)
Provisional Application
63209221
· Jun 10, 2021
References Cited (239)
US 4548922A
· Carey et al.
· 1985
[cited by applicant]
US 4746508A
· Carey et al.
· 1988
[cited by applicant]
US 5023252A
· Hseih
· 1991
[cited by applicant]
US 5240149A
· Schmidt
· 1993
[cited by applicant]
US 5328099A
· Petit et al.
· 1994
[cited by applicant]
US 5568884A
· Bruna
· 1996
[cited by applicant]
US 5731303A
· Hsieh
· 1998
[cited by applicant]
US 5901883A
· Ritsche
· 1999
[cited by applicant]
US 5911937A
· Hekal
· 1999
[cited by applicant]
US 6029663A
· Eisele et al.
· 2000
[cited by applicant]
US 6080350A
· Hekal
· 2000
[cited by applicant]
US 6124006A
· Hekal
· 2000
[cited by applicant]
US 6130263A
· Hekal
· 2000
[cited by applicant]
US 6174952B1
· Hekal et al.
· 2001
[cited by applicant]
US 6179164B1
· Fuchs
· 2001
[cited by applicant]
US 6194079B1
· Hekal
· 2001
[cited by applicant]
US 6209760B1
· Fuchs
· 2001
[cited by applicant]
US 6214255B1
· Hekal
· 2001
[cited by applicant]
US 6221446B1
· Hekal
· 2001
[cited by applicant]
US 6234366B1
· Fuchs
· 2001
[cited by applicant]
US 6264065B1
· Jouillat
· 2001
[cited by applicant]
US 6367473B1
· Käfer
· 2002
[cited by applicant]
US 6398074B1
· Bruna et al.
· 2002
[cited by applicant]
US 6425499B1
· Guiffray
· 2002
[cited by applicant]
US 6427680B1
· Oechsel
· 2002
[cited by applicant]
US 6450216B1
· Stradella
· 2002
[cited by applicant]
US 6461322B1
· Ritsche
· 2002
[cited by applicant]
US 6484715B1
· Ritsche et al.
· 2002
[cited by applicant]
US 6486231B1
· Hekal
· 2002
[cited by applicant]
US 6626379B1
· Ritsche et al.
· 2003
[cited by applicant]
US 6679248B2
· Stadelhofer
· 2004
[cited by applicant]
US 6708846B1
· Fuchs et al.
· 2004
[cited by applicant]
US 6725857B2
· Ritsche
· 2004
[cited by applicant]
US 6877672B2
· Stihl
· 2005
[cited by applicant]
US 6886556B2
· Fuchs
· 2005
[cited by applicant]
US 7005459B2
· Hekal
· 2006
[cited by applicant]
US 7011234B2
· Stradella
· 2006
[cited by applicant]
US 7216781B2
· Duquet et al.
· 2007
[cited by applicant]
US 7353971B2
· Stradella
· 2008
[cited by applicant]
US 7387265B2
· Hess et al.
· 2008
[cited by applicant]
US 7389946B2
· Bruna et al.
· 2008
[cited by applicant]
US 7861943B2
· Feriani et al.
· 2011
[cited by applicant]
US 7878352B2
· Spreckelsen et al.
· 2011
[cited by applicant]
US 7946455B2
· Ritsche et al.
· 2011
[cited by applicant]
US 7947742B2
· Batycky et al.
· 2011
[cited by applicant]
US 7950391B2
· Fuchs
· 2011
[cited by applicant]
US 7954491B2
· Hrkach
· 2011
[cited by applicant]
US 8016209B2
· Hess et al.
· 2011
[cited by applicant]
US 8263581B2
· Du
· 2012
[cited by applicant]
US 8337817B2
· Nagata et al.
· 2012
[cited by applicant]
US 8415397B2
· Batycky et al.
· 2013
[cited by applicant]
US 8481043B2
· Bergenhem et al.
· 2013
[cited by applicant]
US 8734392B2
· Stadelhofer
· 2014
[cited by applicant]
US 8747813B2
· Batycky et al.
· 2014
[cited by applicant]
US 9156048B2
· Maner
· 2015
[cited by applicant]
US 9789071B2
· Fleming
· 2017
[cited by applicant]
US 9808818B2
· Maner
· 2017
[cited by applicant]
US 9834341B2
· Giraud et al.
· 2017
[cited by applicant]
US 9902788B2
· Klein et al.
· 2018
[cited by applicant]
US 20020079326A1
· Fuchs
· 2002
[cited by applicant]
US 20040084554A1
· Milian
· 2004
[cited by applicant]
US 20070272764A1
· Poulard
· 2007
[cited by applicant]
US 20080269347A1
· Bruss et al.
· 2008
[cited by applicant]
US 20090220435A1
· Quay et al.
· 2009
[cited by applicant]
US 20100055152A1
· Wahi
· 2010
[cited by applicant]
US 20100078447A1
· Sauzade et al.
· 2010
[cited by applicant]
US 20110194110A1
· Langeard et al.
· 2011
[cited by applicant]
US 20110233232A1
· Greiner-Perth et al.
· 2011
[cited by applicant]
US 20120318677A1
· Bruna et al.
· 2012
[cited by applicant]
US 20130022750A1
· Bruna et al.
· 2013
[cited by applicant]
US 20130081953A1
· Bruna et al.
· 2013
[cited by applicant]
US 20130149459A1
· Bruna et al.
· 2013
[cited by applicant]
US 20130171330A1
· Sallak et al.
· 2013
[cited by applicant]
US 20130171334A1
· Bruna et al.
· 2013
[cited by applicant]
US 20130312740A1
· Pardonge
· 2013
[cited by applicant]
US 20140034663A1
· Königseder et al.
· 2014
[cited by applicant]
US 20150299846A1
· Bruna et al.
· 2015
[cited by applicant]
US 20160220489A1
· Fleming et al.
· 2016
[cited by applicant]
US 20170304459A1
· Jadhav et al.
· 2017
[cited by applicant]
US 20180056022A1
· Liu et al.
· 2018
[cited by applicant]
US 20190269782A1
· Lowenthal et al.
· 2019
[cited by applicant]
US 20190358417A1
· Brouet et al.
· 2019
[cited by applicant]
US 20200085765A1
· Rubin
· 2020
[cited by applicant]
US 20200155775A1
· Keppner et al.
· 2020
[cited by applicant]
US 20200164164A1
· Helmlinger et al.
· 2020
[cited by applicant]
US 20210069126A1
· Fleming
· 2021
[cited by applicant]
US 20210205238A1
· Augustin et al.
· 2021
[cited by applicant]
US 20210264716A1
· Norbeck
· 2021
[cited by examiner]
US 20220218629A1
· Rawas-Qalaji et al.
· 2022
[cited by applicant]
US 20230144040A1
· Brouet et al.
· 2023
[cited by applicant]
US 20230225994A1
· Howard et al.
· 2023
[cited by applicant]
US 20240245856A1
· Krishnan et al.
· 2024
[cited by applicant]
US 20240252489A1
· Hoekman et al.
· 2024
[cited by applicant]
US 20240261227A1
· Ogburn et al.
· 2024
[cited by applicant]
US 20240342117A1
· Fraser et al.
· 2024
[cited by applicant]
US 20240366533A1
· Howard et al.
· 2024
[cited by applicant]
US 20240408212A1
· Sämarker et al.
· 2024
[cited by applicant]
US 20250000821A1
· Zhang
· 2025
[cited by applicant]
US 20250009995A1
· Walsh et al.
· 2025
[cited by applicant]
US 20250041544A1
· Haruta
· 2025
[cited by applicant]
US 20250099374A1
· Boyer et al.
· 2025
[cited by applicant]
US 20250108017A1
· Schobel et al.
· 2025
[cited by applicant]
US 20250114307A1
· Eber et al.
· 2025
[cited by applicant]
US 20250195436A1
· Eber et al.
· 2025
[cited by applicant]
US 20250195470A1
· Gandhi et al.
· 2025
[cited by applicant]
US 20250205224A1
· Sämarker et al.
· 2025
[cited by applicant]
WO WO9732663A1
· 1997
[cited by examiner]
WO 2003037355A1
· 2003
[cited by applicant]
WO WO2015034822A1
· 2015
[cited by examiner]
Epi-Temp Case (Available online Aug. 5, 2018) (Year: 2018).
[cited by examiner]
Wayback Machine Print out, accessed Jul. 30, 2025. (Year: 2025).
[cited by examiner]
Bebarta VS, Pitotti RL, Dixon PS, Valtier S, Esquivel L, Bush A, Little CM. Hydroxocobalamin and epinephrine both improve survival in a swine model of cyanide-induced cardiac arrest. Ann Emerg Med. Oct. 2012;60(4):415-2…
[cited by applicant]
Bourganis V, Kammona O, Alexopoulos A, Kiparissides C. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. Eur J Pharm Biopharm. Jul. 2018;128:337-362. doi: 10.1016/j.ejpb.2018.05.009. Epub May …
[cited by applicant]
Brown JC, Tuuri RE, Akhter S, Guerra LD, Goodman IS, Myers SR, Nozicka C, Manzi S, Long K, Turner T, Conners GP, Thompson RW, Park E. Lacerations and Embedded Needles Caused by Epinephrine Autoinjector Use in Children. …
[cited by applicant]
Casematrix, Cases for Inhalers, insulin, medical devices and more, available online Jan. 24, 2021). (Year: 2021).
[cited by applicant]
Chooniedass R, Temple B, Becker A. Epinephrine use for anaphylaxis: Too seldom, too late: Current practices and guidelines in health care. Ann Allergy Asthma Immunol. Aug. 2017;119(2):108-110. doi: 10.1016/j.anai.2017.0…
[cited by applicant]
Chowdhury BA, Meyer RJ. Intramuscular versus subcutaneous injection of epinephrine in the treatment of anaphylaxis J Allergy Clin Immunol. Apr. 2002;109(4):720; author reply 720-1. doi: 10.1067/mai.2002.123252. PMID: 11…
[cited by applicant]
Clutter WE, Bier DM, Shah SD, Cryer PE. Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. J Clin Invest. Jul. 1980;66(1):94-101. doi: 10.1172/JCI109840…
[cited by applicant]
Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm. Jun. 7, 2007;337(1-2):1-24. doi: 10.1016/j.ijpharm.2007.03.025. Epub Mar. 25, 2007. PMID:…
[cited by applicant]
D Tabor, Surface forces and surface interactions, J. Colloid Interface Sci., vol. 58, Issue 1, 1977, pp. 2-13, https://doi.org/10.1016/0021-9797(77)90366-6.
[cited by applicant]
Davis SS, Illum L. Absorption enhancers for nasal drug delivery. Clin Pharmacokinet. 2003;42(13):1107-28. doi: 10.2165/00003088-200342130-00003. PMID: 14531723.
[cited by applicant]
Dodd A, Hughes A, Turner PJ, 2021, Anaphylaxis management—Why are guidelines inconsistent?: A rapid review of advanced life support guidelines for cardiac arrest associated with anaphylaxis., Resuscitation, vol. 159, pp…
[cited by applicant]
Dreborg S, Kim H. The pharmacokinetics of epinephrine/adrenaline autoinjectors. Allergy Asthma Clin Immunol. Mar. 8, 2021;17(1):25. doi: 10.1186/s13223-021-00511-y. PMID: 33685510; PMCID: PMC7938517.
[cited by applicant]
Dvauchelle T, Robert P, Donazzolo Y, Loyau S, Orlandini B, Lehert P, Lecomte JM, Schwartz JC. Bioavailability and Cardiovascular Effects of Adrenaline Administered by Anapen Autoinjector in Healthy Volunteers. J Allergy…
[cited by applicant]
Fleming, J.T., et al., “Early Treatment of Food-Induced Anaphylaxis with Epinephrine Is Associated with a Lower Risk of Hospitalization,” J. Allergy Clin Immunol Pract., Jan.-Feb. 2015; 3(1):57-62; doi: 10.1016/j.jaip.2…
[cited by applicant]
Gabrielli, S., et al., “Teenagers and those with severe reactions are more likely to use their epinephrine autoinjectors in cases of anaphylaxis in Canada,” J. Allergy & Clin. Immunology: In Practice, Clinical Communica…
[cited by applicant]
Gänger S, Schindowski K. Tailoring Compositions for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa. Pharmaceutics. A…
[cited by applicant]
Gill MA, Kislik AZ, Gore L, Chandna A. Stability of advanced life support drugs in the field. Am J Health Syst Pharm. Mar. 15, 2004;61(6):597-602. doi: 10.1093/ajhp/61.6.597. PMID: 15061431.
[cited by applicant]
Greenberger PA, Wallace DV, Lieberman PL, Gregory SM. Contemporary issues in anaphylaxis and the evolution of epinephrine autoinjectors: What will the future bring? Ann Allergy Asthma Immunol. Oct. 2017;119(4):333-338. …
[cited by applicant]
Haidar SH, Makhlouf F, Schuirmann DJ, Hyslop T, Davit B, Conner D, Yu LX. Evaluation of a scaling approach for the bioequivalence of highly variable drugs. AAPS J. Sep. 2008;10(3):450-4. doi: 10.1208/s12248-008-9053-4. …
[cited by applicant]
Hill RL, Wilmot JG, Belluscio BA, Cleary K, Lindisch D, Tucker R, Wilson E, Shukla RB. Comparison of drug delivery with autoinjector versus manual prefilled syringe and between three different autoinjector devices admin…
[cited by applicant]
Illium L and Fisher AN (1997) Intranasal delivery of peptides and proteins, in Inhalation Delivery of Therapeutic Peptides and Proteins (Adjei AL and Gupta PK eds), Marcel Dekker, New York.
[cited by applicant]
Internet webpages, “2 Pack Molle Pouches—Tactical Compact Water-Resistant EDC Pouch”, Mar. 5, 2019, pp. 1-5, https://www.amazon.com/Pack-Molle-Pouches-Tactical-Water-Resistant/dp/B07PFF47DX?th=1.
[cited by applicant]
Johnstone J, Hobbins S, Parekh D, O'Hickey S. Excess subcutaneous tissue may preclude intramuscular delivery when using adrenaline autoinjectors in patients with anaphylaxis. Allergy. Jun. 2015;70(6):703-6. doi: 10.1111…
[cited by applicant]
Judenherc-Haouzl A, Sonobe T, Bebarta VS, Haouzi P. On the Efficacy of Cardio-Pulmonary Resuscitation and Epinephrine Following Cyanide- and H2S Intoxication-Induced Cardiac Asystole. Cardiovasc Toxicol. Oct. 2018;18(5)…
[cited by applicant]
Karalis V, Symillides M, Macheras P. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs. Eur J Pharm Sci. Aug. 12, 2009;38(1):55-63. doi: 10.1…
[cited by applicant]
Kassel L, Jones C, Mengesha A. Epinephrine drug degradation in autoinjector products. J Allergy Clin Immunol Pract. Sep.-Oct. 2019;7(7):2491-2493. doi: 10.1016/j.jaip.2019.04.028. Epub May 28, 2019. PMID: 31151888.
[cited by applicant]
Kemp SF, Lockey RF, Simons FE; World Allergy Organization ad hoc Committee on Epinephrine in Anaphylaxis. Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization. Allergy. Aug. 200…
[cited by applicant]
Kuehl PJ, Barrett EG, Cox J, Hammond B, Rudolph K, Suman JD, Williams G, Vermillion M., Nasal Sumatriptan: Deposition and Pharmacokinetic Effect of an Absorption Enhancer in Non-Human Primates, Respiratory Drug Delivery…
[cited by applicant]
Lacwik, P., et. at., “Single, short-time exposure to heat in a car during sunny day can decrease epinephrine concentration in autoinjectors: a real-life pilot study,” J. Allergy & Clin. Immunology, Apr. 1, 2019, 7(4): P…
[cited by applicant]
Lam C, Turner P, Hemming D, et al., 2021, Seasonality of food related anaphylaxis admissions and associations with temperature and pollen levels, Journal of Allergy and Clinical Immunology: in Practice, vol. 9, ISSN:221…
[cited by applicant]
Miles LM, Ratnarajah K, Gabrielli S, Abrams EM, Protudjer JLP, Begin P, Chan ES, Upton J, Waserman S, Watson W, Gerdts J, Ben-Shoshan M. Community Use of Epinephrine for the Treatment of Anaphylaxis: A Review and Meta-A…
[cited by applicant]
Moss, J, Jani, Y, Edwards, B, Tomlin, S, Rashed, AN. Pharmacokinetic and pharmacodynamic evidence of adrenaline administered via auto-injector for anaphylactic reactions: A review of literature. Br J Clin Pharmacol. 202…
[cited by applicant]
Muraro A, Worm M, Alviani C, Cardona V, DunnGalvin A, Garvey LH, Riggioni C, de Silva D, Angier E, Arasi S, Bellou A, Beyer K, Bijlhout D, Bilo MB, Bindslev-Jensen C, Brockow K, Fernandez-Rivas M, Halken S, Jensen B, Kh…
[cited by applicant]
Okubo M, Komukai S, Callaway CW, Izawa J. Association of Timing of Epinephrine Administration With Outcomes in Adults With Out-of-Hospital Cardiac Arrest. JAMA Netw Open. Aug. 2, 2021;4(8):e2120176. doi: 10.1001/iamanet…
[cited by applicant]
Parish HG, Bowser CS, Morton JR, Brown JC. A systematic review of epinephrine degradation with exposure to excessive heat or cold. Ann Allergy Asthma Immunol. Jul. 2016;117(1):79-87. doi: 10.1016/j.anai.2016.04.006. Epu…
[cited by applicant]
Patel N, Chong KW, Yip AYG, lerodiakonou D, Bartra J, Boyle RJ, Turner PJ. Use of multiple epinephrine doses in anaphylaxis: A systematic review and meta-analysis. J Allergy Clin Immunol. Nov. 2021;148(5):1307-1315. doi…
[cited by applicant]
Patil Armenian, Danielle Campagne, Geoff Stroh, Crystal Ives Tallman, William Z. D. Zeng, Thomas Lin & Roy R. Gerona (2017) Hot and Cold Drugs: National Park Service Medication Stability at the Extremes of Temperature, …
[cited by applicant]
Paul Turner, Imperial College London. Pharmacokinetics of Intramuscular Adrenaline in Food—Allergic Teenagers: Does Dose Matter? The PIMAT Study. Version 1.2, Sep. 29, 2017.
[cited by applicant]
Ponda P, Russell AF, Yu JE, Land MH, Crain MG, Patel K, Shroba JA, Sriaroon P. Access barriers to epinephrine autoinjectors for the treatment of anaphylaxis: A survey of practitioners. J Allergy Clin Immunol Pract. Oct.…
[cited by applicant]
Prince BT, Mikhail I, Stukus DR. Underuse of epinephrine for the treatment of anaphylaxis: missed opportunities. J Asthma Allergy. Jun. 20, 2018;11:143-151. doi: 10.2147/JAA.S159400. PMID: 29950873; PMCID: PMC6016581.
[cited by applicant]
Proxim/Proximed, Directions for use: Nasal Turbuhaler, available online Sep. 30, 2020). (Year: 2020).
[cited by applicant]
Rachid O, Simons FE, Rawas-Qalaji M, Lewis S, Simons KJ. Epinephrine doses delivered from auto-injectors stored at excessively high temperatures. Drug Dev Ind Pharm. Jan. 2016;42(1):131-135. doi: 10.3109/03639045.2015.1…
[cited by applicant]
Rawas-Qalaji M, Simons FE, Collins D, Simons KJ. Long-term stability of epinephrine dispensed in unsealed syringes for the first-aid treatment of anaphylaxis. Ann Allergy Asthma Immunol. Jun. 2009;102(6):500-3. doi: 10.…
[cited by applicant]
Robert J Good, Surface free energy of solids and liquids: Thermodynamics, molecular forces, and structure, J. Colloid Interface Sci., vol. 59, Issue 3, 1977, pp. 398-419, https://doi.org/10.1016/0021-9797(77)90034-0.
[cited by applicant]
Roth JV, Shields A. A dilemma: How does one treat anaphylaxis in the sulfite allergic patient since epinephrine contains sodium metabisulfite? Anesth Analg. May 2004;98(5):1499; author reply 1500. doi: 10.1213/01.ane.00…
[cited by applicant]
Rygg A, Hindle M, Longest PW. Linking Suspension Nasal Spray Drug Deposition Patterns to Pharmacokinetic Profiles: A Proof-of-Concept Study Using Computational Fluid Dynamics. J Pharm Sci. Jun. 2016;105(6):1995-2004. do…
[cited by applicant]
Satish Balakrishna Bhise, Adhikrao Vyankatrao Yadav, Amelia Makrand Avachat, Rajkumar Malayandi, Bioavailability of intranasal drug delivery system, Biopharmaceutical Research Group, Department of Biopharmaceutics, Gove…
[cited by applicant]
Sclar DA. Bioequivalence evaluation of epinephrine autoinjectors with attention to rapid delivery. Ther Clin Risk Manag. 2013;9:149-51. doi: 10.2147/TCRM.S43774. Epub Apr. 12, 2013. PMID: 23610523; PMCID: PMC3629870.
[cited by applicant]
Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol. Nov. 2001;108(5):871-3. doi: 10.1067/mai.2001.119409. PMID: 11692118.
[cited by applicant]
Simons FE, Lieberman PL, Read EJ Jr, Edwards ES. Hazards of unintentional injection of epinephrine from autoinjectors: a systematic review. Ann Allergy Asthma Immunol. Apr. 2009;102(4):282-7. doi: 10.1016/S1081-1206(10)…
[cited by applicant]
Simons FE, Roberts JR, Gu X, Simons KJ. Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol. Jan. 1998;101(1 Pt 1):33-7. doi: 10.1016/S0091-6749(98)70190-3. PMID: 9449498.
[cited by applicant]
Song TT, Nelson MR, Chang JH, Engler RJ, Chowdhury BA. Adequacy of the epinephrine autoinjector needle length in delivering epinephrine to the intramuscular tissues. Ann Allergy Asthma Immunol. May 2005;94(5):539-42. do…
[cited by applicant]
Stetcher, D., et.al., “Epinephrine Auto-injectors: Is Needle Length Adequate for Delivery of Epinephrine Intramuscularly?” Pediatrics, Jul. 2009, 124(1): 65-70, doi:10.1542/peds.2008-3388.
[cited by applicant]
Susan C. Smolinske (1992) Review of Parenteral Sulfite Reactions, Journal of Toxicology: Clinical Toxicology, 30:4, 597-606, DOI: 10.3109/15563659209017945.
[cited by applicant]
Takeuchi H, Thongborisute J, Matsui Y, Sugihara H, Yamamoto H, Kawashima Y. Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems. Adv Drug Deliv Rev. No…
[cited by applicant]
Tiozzo Fasiolo L, Manniello MD, Tratta E, Buttini F, Rossi A, Sonvico F, Bortolotti F, Russo P, Colombo G. Opportunity and challenges of nasal powders: Drug composition and delivery. Eur J Pharm Sci. Feb. 15, 2018;113:2…
[cited by applicant]
Turner P, 2021, A Cost-effectiveness Analysis of Epinephrine Autoinjector Risk Stratification for Patients with Food Allergy—One Epinephrine Autoinjector or Two?, Journal of Allergy and Clinical Immunology: in Practice,…
[cited by applicant]
Turner P, Boyle R, Durham S, 2021, Limited effect of intramuscular epinephrine on cardiovascular parameters during peanut-induced anaphylaxis: an observational cohort study, Journal of Allergy and Clinical Immunology: i…
[cited by applicant]
Turner P, Patel N, 2021, Using data from food challenges to inform management of food-allergic consumers: a systematic review with individual participant data meta-analysis, Journal of Allergy and Clinical Immunology, I…
[cited by applicant]
Turner PJ, Ruiz-Garcia M, Durham SR, Boyle RJ. Limited effect of intramuscular epinephrine on cardiovascular parameters during peanut-induced anaphylaxis: An observational cohort study. J Allergy Clin Immunol Pract. Jan…
[cited by applicant]
U.S. Food & Drug Administration. Multidisciplinary Review. NDA 201-739, S-008 and S-009. Auvi-Q (epinephrine injection, USP) Auto-Injector. Sep. 2017, available at www.fda.gov/media/109468/download.
[cited by applicant]
US FDA, FY2018 Regulatory Science Report: Physiologically-Based Absorption and Pharmacokinetic Models for Non-Oral Routes, https://www.fda.gov/media/130623/download (last accessed Jun. 10, 2021).
[cited by applicant]
Wasserman, S., et al. “Epinephrine Autoinjectors: New Data, New Problems,” J Allergy Clin Immunol Pract., Sep.-Oct. 2017; 5(5):1180-1191, doi: 10.1016/j.jaip.2017.06.027.
[cited by applicant]
Worm, M., Nguyen, D., Rackley, R. et al. Epinephrine delivery via EpiPen® Auto-Injector or manual syringe across participants with a wide range of skin-to-muscle distances. Clin Transl Allergy 10, 21 (2020). https://doi…
[cited by applicant]
Bleske BE, Warren EW, Rice TL, Shea MJ, Amidon G, Knight P. Comparison of intravenous and intranasal administration of epinephrine during CPR in a canine model. Ann Emerg Med. Sep. 1992;21(9):1125-30. doi: 10.1016/s0196…
[cited by applicant]
Casale, Thomas B. et al., Pharmacokinetics/pharmacodynamics of epinephrine after single and repeat administration of neffy, EpiPen, and manual intramuscular injection, Journal of Allergy and Clinical Immunology, Dec. 20…
[cited by applicant]
Cited By (3)